Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib in Moderate to Severe Active Ulcerative Colitis
NCT03675477Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ivarmacitinib in ulcerative colitis (UC) (4 arms), sponsored by Reistone Biopharma. Primary endpoint: Percentage of Subjects Achieving Clinical Response at 8 weeks. Started Apr 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03675477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675477.